摘要
目的 探讨卡瑞利珠单抗联合替吉奥治疗晚期食管癌的临床疗效及安全性。方法 按照治疗方式的不同将116例晚期食管癌患者分为对照组和联合组,每组58例,对照组患者接受卡瑞利珠单抗治疗,联合组患者接受卡瑞利珠单抗联合替吉奥治疗。比较两组患者的临床疗效、肿瘤标志物[癌胚抗原(CEA)、鳞状细胞癌抗原(SCC-Ag)、糖类抗原125(CA125)和血管内皮生长因子(VEGF)]水平、T淋巴细胞亚群(CD3+、CD4+、CD4+/CD8+)水平和不良反应发生情况。结果 联合组患者疾病控制率为94.83%,明显高于对照组患者的72.41%,差异有统计学意义(P﹤0.01)。治疗后,两组患者CEA、SCC-Ag、VEGF、CA125水平均低于本组治疗前,联合组患者CEA、SCC-Ag、VEGF、CA125水平均低于对照组,差异均有统计学意义(P﹤0.05)。治疗后,两组患者CD3+、CD4+水平和CD4+/CD8+均低于本组治疗前,联合组患者CD3+、CD4+水平和CD4+/CD8+均高于对照组,差异均有统计学意义(P﹤0.05)。联合组患者的不良反应总发生率为6.90%,低于对照组患者的22.41%,差异有统计学意义(P﹤0.05)。结论 卡瑞利珠单抗联合替吉奥治疗晚期食管癌疗效较好,对患者免疫功能的影响较小,可降低不良反应发生率,提高生活质量。
Objective To analyze the clinical efficacy and safety of camrelizumab combined with S-1 in the treat-ment of advanced esophageal cancer.Method According to different treatment methods,116 patients with advanced esophageal cancer were divided into control group and combination group,with 58 cases in each group.The control group received camrelizumab treatment,while the combination group received camrelizumab combined with S-1 treat-ment.The clinical efficacy,levels of tumor markers[carcinoembryonic antigen(CEA),squamous cell carcinoma antigen(SCC-Ag),carbohydrate antigen 125(CA125),vascular endothelial growth factor(VEGF)],T lymphocyte subsets(CD3+,CD4+,CD4+/CD8+)levels,and incidence of adverse reactions were compared between the two groups.Result The dis-ease control rate of the combination group was 94.83%,which was significantly higher than 72.41%of the control group,the difference was statistically significant(P<0.01).After treatment,the levels of CEA,SCC-Ag,VEGF,and CA125 in both groups were lower than those before treatment,the levels of CEA,SCC-Ag,VEGF,and CA125 in the combination group were lower than those in the control group,and the differences were statistically significant(P<0.05).After treat-ment,the levels of CD3+,CD4+,and CD4+/CD8+in both groups were lower than those before treatment,the levels of CD3+,CD4+,and CD4+/CD8+in the combination group were higher than those in the control group,and the differences were statistically significant(P<0.05).The total incidence of adverse reactions in the combination group was 6.90%,which was lower than 22.41%in the control group,and the difference was statistically significant(P<0.05).Conclusion Camrelizumab combined with S-1 in the treatment of advanced esophageal cancer has a good therapeutic effect,with min-imal impact on the patient’s immune function,and can reduce the incidence of adverse reactions,and improve quality of life.
作者
闫桂军
杜海艳
江红
YAN Guijun;DU Haiyan;JIANG Hong(Department of Oncology,the People’s Hospital of Jiawang District of Xuzhou City,Xuzhou 221011,Jiangsu,China)
出处
《癌症进展》
2024年第11期1256-1259,共4页
Oncology Progress
基金
吴阶平医学基金会临床科研专项(320.6750.2021-06-59)
